Karyopharm posts positive data from Phase III trial of multiple myeloma drug

Karyopharm posts positive data from Phase III trial of multiple myeloma drug

The trial, of Xpovio, showed a positive increase in progression-free survival in patients with second-line disease. Xpovio’s accelerated approval last year for heavily pretreated patients attracted controversy from the myeloma physician community.

Source: https://ift.tt/2PKUjH2